2022 World Conference on Lung Cancer (ePosters)-EP08.02-162. Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

EP08.02-162. Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

Back to course

Pdf Summary

This document presents a case series on the efficacy and safety of the combination of tepotinib and EGFR-TKIs in patients with EGFR-mutant MET-amplified non-small cell lung cancer (NSCLC). The study included 12 patients with a variety of characteristics, such as age, gender, smoking history, and histology.<br /><br />The patients received tepotinib in combination with an EGFR-TKI in second, third, or fourth line of treatment. The treating physicians assessed that 11 patients had clinical benefit, with eight patients considered to have a partial response. Four specific cases were highlighted in more detail.<br /><br />The main safety concern associated with tepotinib was peripheral edema, reported in seven patients. Other adverse events included dermatitis, elevated amylase and lipase levels, and pneumonia. However, no grade 4 or 5 adverse events related to tepotinib were reported.<br /><br />The combination of tepotinib and EGFR-TKIs showed promising clinical activity in this case series of patients with EGFR-mutant MET-amplified NSCLC who had previously progressed on EGFR-TKIs. The results suggest that the combination may overcome MET-related resistance to EGFR-TKIs.<br /><br />It is notable that tepotinib has been investigated in the INSIGHT 2 study in patients with EGFR-mutant MET-amplified NSCLC who have acquired resistance to first-line osimertinib.<br /><br />In conclusion, this case series provides evidence suggesting that the combination of tepotinib and EGFR-TKIs may be an effective treatment option for patients with EGFR-mutant MET-amplified NSCLC who have progressed on EGFR-TKIs. Further research, including ongoing clinical trials, is warranted to validate these findings and establish the optimal use of this combination therapy.

Asset Subtitle

Xiuning Le

Meta Tag

Speaker Xiuning Le

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

tepotinib

EGFR-TKIs

efficacy

safety

combination therapy

non-small cell lung cancer

NSCLC

MET amplification

clinical activity

adverse events